Drug Trial Radar · NCT07422389
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- BRIM Biotechnology Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Pennsylvania
- First posted
- Feb 20, 2026
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: * Use BRM421 two times a day for at least 12 weeks * Visit the clinic monthly for checkups and tests
Conditions
- Limbal Stem Cell Deficiency (LSCD)
Interventions
BRM421 Ophthalmic Solution, 0.06%Drug
Patients eligible to participate will receive 0.06% BRM421 Ophthalmic Solutions to be administered two times daily (BID, morning and bedtime) on the eligible eye(s). The administration will be at least 12 weeks. The investigator may continue the treatment beyond the 12 weeks based on clinical response. For patients scheduled for LSC transplant, treatment with BRM421 should start only after surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scheie Eye Institute
Philadelphia, Pennsylvania · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.